US patent

The US Patent and Trademark Office (USPTO) has granted a patent for Axcella Therapeutics’ long Covid treatment candidate AXA1125. AXA1125 is a novel composition of endogenous metabolic modulators (EMMs) designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with fatigue. In April, The Lancet published the results of Axcella’s Phase IIa trial, which showed […]

bit.bio has secured a foundational US patent for opti-ox, its precision cell programming and manufacturing technology. opti-ox uses a dual genomic safe harbour approach to cell programming, and the granted US patent covers the use of opti-ox to deterministically activate genetic code in any eukaryotic (cell with a nucleus) cell type. bit.bio uses opti-ox to […]

The United States Patent and Trademark Office (USPTO) has granted Gedea Biotech’s patent application 16/753,899 directed to gluconic acid derivatives for preventing and/or treating bacterial infections. The patent can be kept in force until 2038. The specific derivative Glucone-delta lactone (GDL) in pHyph is a well-documented substance with a low risk of developing antimicrobial resistance. […]

The United States Patent Office (USPTO) has issued a patent covering drug candidate ACD856, which is currently being developed to treat Alzheimer’s disease and other disorders with cognitive impairment. ACD856 is part of AlzeCure Pharma’s NeuroRestore platform, which it is hoped could provide treatments for Alzheimer’s, Parkinson’s disease and depression. These drugs stimulate several important […]